WebFeb 15, 2024 · Purpose This phase 1 trial evaluated the safety, preliminary efficacy, and pharmacokinetics of surufatinib, a small molecular tyrosine kinase inhibitor, combined … WebThe PD-1 antibody, teripalimab, is an immunological checkpoint inhibitor that has shown clinical efficacy in advanced esophageal cancer, but there has been relatively few data on neoadjuvant therapy. This study was designed to comprehend the pathological complete response rate, disease-free survival, and safety of neoadjuvant therapy with ...
A phase II, single-centre trial of neoadjuvant toripalimab plus ...
WebMar 5, 2024 · Esophageal cancer (EC) is one of the most common cancers with poor survival in the world. Nowadays, a generous number of clinical trials are underway on the use of immunotherapy in EC patients, especially the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors. However, only a few patients could benefit from … WebNov 25, 2024 · Registry name: “Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer”. Keywords: Esophageal cancer; neoadjuvant … tristan gatto yoga shred review
Teripalimab Plus Chemotherapy in Local Advanced …
WebJun 20, 2024 · Phase II/III Trial of Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab Versus EP/EC in Advanced or Metastatic Neuroendocrine Carcinoma: … WebPhase II/III Trial of Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab Versus EP/EC in Advanced or Metastatic Neuroendocrine Carcinoma : Secondary IDs: Study Status. Record Verification: June 2024 : Overall Status: Recruiting: Study Start: June 19, 2024 : Primary Completion: WebTeripalimab. Status: Unknown status. Location: See location... Intervention Type: Drug. Study Type: Interventional. Study Phase: Phase 2. Summary. This study will evaluate the safety and feasibility of preoperative immune checkpoint therapy with concurrent Chemoradiotherapy in patients with locally advanced esophageal squamous cell … tristan fulchiron